The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection

Baak, B.C.; Bakker, C.M.; Beuers, U.H.; Brouwer, J.T.; Buster, E.H.; Drenth, J.P.H.; Erpecum, K.J. van; Hoek, B. van; Honkoop, P.; Janssen, H.L.; Kerbert-Dreteler, M.J.; Koek, G.H.; Nieuwkerk, K.M. van; Tan, A.C.; van der Spek, B.W.; van Soest, H.; Vrolijk, J.M.

The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection

Authors: B.C. Baak
C.M. Bakker
U.H. Beuers
J.T. Brouwer
E.H. Buster
J.P.H. Drenth
K.J. van Erpecum
B. van Hoek
P. Honkoop
H.L. Janssen
M.J. Kerbert-Dreteler
G.H. Koek
K.M. van Nieuwkerk
A.C. Tan
B.W. van der Spek
H. van Soest
J.M. Vrolijk
Publication date: 1 January 2012
Publisher

Abstract

Item does not contain fulltextIn 2008, the Netherlands Association of Gastroenterologists and Hepatologists (Nederlands Vereniging van Maag-Darm-Leverartsen) published the Dutch national guidelines for the treatment of chronic hepatitis B virus infection. New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines. The most important changes include the choice of initial antiviral therapy, licensing of tenofovir for the treatment of chronic hepatitis B and the management of antiviral resistance